[1] Chandrasekar , P.,Manavathu , E.,,2001,,,,-
[2] DrugsToday,,,,,37,135-148
[3] Cronin , S.,Chandrasekar , P. H.,,2009,Safety of triazole antifungal drugs in patients with cancer,,,-
[4] ,,,Journal of antimicrobial chemotherapy,65,410-416
[5] Dolton , M. J.,Ray , J. E.,Chen,Ng , K.,Pont , L. G.,McLachlan , A. J.,,2012,-,,,-
[6] ,,Multicenter study of voriconazole pharmacokinetics and therapeutic drug monitoring,Antimicrobial agents and chemotherapy,56,4793-4799
[7] Lortholary , O.,,2002,Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis,New England Journal of Medicine,347,408-415
[8] Hussaini , T.,Rüping , M. J.,Farowski , F.,Vehreschild , J. J.,Cornely , O. A.,,2011,,,,-
[9] ,,Therapeutic drug monitoring of voriconazole and posaconazole,Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,31,214-225
[10] Kim , S.-H.,Yim,Choi , S.-M.,Kwon,Han , S.,Lee,Choi , J.-H.,,2011,,,,-
[11] ,,Voriconazole-related severe adverse events: clinical application of therapeutic drug monitoring in Korean patients,International Journal of Infectious Diseases,15,e753-e758
[12] Kontoyiannis , D. P.,,2012,Invasive mycoses: strategies for effective management,The American journal of medicine,125,S25-S38
[13] Haefeli , W. E.,,2006,Potent cytochrome P450 2C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir,Clinical Pharmacology & Therapeutics,80,126-135
[14] Nivoix , Y.,Levêque , D.,Herbrecht , R.,Koffel , J.-C.,Beretz , L.,Ubeaud-Sequier , G.,,2008,The enzymatic basis of drug-drug interactions with systemic triazole antifungals,Clinical pharmacokinetics,47,779-792
[15] Nivoix , Y.,Ubeaud-Sequier , G.,Engel , P.,Levêque , D.,Herbrecht , R.,,2009,Drug-drug interactions of triazole antifungal agents in multimorbid patients and implications for patient care,Current drug metabolism,10,395-409
[16] Pascual , A.,Calandra , T.,Bolay , S.,Buclin , T.,Bille , J.,Marchetti , O.,,2008,Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes,Clinical infectious diseases,46,201-211
[17] Pascual , A.,Nieth , V.,Calandra , T.,Bille , J.,Bolay , S.,Decosterd , L. A.,Marchetti , O.,,2007,,,,-
[18] ,,,Antimicrobial agents and chemotherapy,51,137-143
[19] Purkins , L.,Wood , N.,Greenhalgh , K.,Eve , M. D.,Oliver , S. D.,Nichols , D.,,2003,The pharmacokinetics and safety of intravenous voriconazole-a novel wide‐spectrum antifungal agent,British journal of clinical pharmacology,56,2-9
[20] Purkins , L.,Wood , N.,Kleinermans , D.,Greenhalgh , K.,Nichols , D.,,2003,Effect of food on the pharmacokinetics of multiple‐dose oral voriconazole,British journal of clinical pharmacology,56,17-23
[21] Mikus , G.,,2005,Opposite effects of short‐term and long‐term St John's wort intake on voriconazole pharmacokinetics,Clinical Pharmacology & Therapeutics,78,25-33
[22] Saad , A. H.,DePestel,Carver , P. L.,,2006,,,,-
[23] ,,,Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy,26,1730-1744
[24] ,2003,Voriconazole: a new triazole antifungal agent,Clinical infectious diseases,36,630-637
[25] Sienkiewicz , B. M.,Łapiński,Wiela-Hojeńska , A.,,2016,Comparison of clinical pharmacology of voriconazole and posaconazole,Contemporary Oncology,20,365-
[26] ,2012,Drug interactions: principles and practice,Australian prescriber,35,85-88
[27] Trifilio , S.,Pennick , G.,Pi , J.,Zook , J.,Golf , M.,Kaniecki , K.,Tallman , M.,,2007,,,,-
[28] Cancer,,,,,109,1532-1535
[29] Walsh , T. J.,Anaissie , E. J.,Denning , D. W.,Herbrecht , R.,Kontoyiannis , D. P.,Marr , K. A.,Stevens , D. A.,,2008,Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America,,,-
[30] ,,,Clinical infectious diseases,46,327-360